Teva Pharmaceutical Finance Company, LLC Credit Rating

Usuarios Registrados

Registro para acceso total permitido. Su código de acceso es sensible a mayúsculas y minúsculas.

Nombre de Usuario:

Código de Acceso:

Ingresarme automáticamente en mi próxima visita

Entrar

Olvidó su Nombre de Usuario o Código de Acceso?

No se ha registrado?

Regístrese ahora para tener acceso GRATUITO a:

Calificaciones de Emisor.

Calificaciones de más de 170,000 instrumentos de corporativos, gobiernos y finanzas estructuradas.

Calendario de Eventos.

Información de cursos de capacitación, seminarios y teleconferencias.

Listas de Calificaciones en Observación.

Listas de emisores en revisión para cambios de calificación.

Metodologías de Calificación.

Marcos descriptivos del sustento de las calificaciones de Moody's.

Resultados 1 - 29 de 29

Página 1 de 1 Next

Filtrar por:

Fecha	Tipo de Informe	Título	Fuente
17 Dec 2023	Rating Action	Moody's affirms Teva's Ba2 ratings; outlook stable	Moody's Investors Service
27 Jul 2023	Announcement of Periodic Review	Moody's announces completion of a periodic review for a group of Pharmaceutical issuers	Moody's Investors Service
04 Oct 2022	Announcement of Periodic Review	Moody's announces completion of a periodic review for a group of Pharmaceutical issuers	Moody's Investors Service
15 Dec 2021	Rating Action	Moody's affirms Teva's Ba2 ratings; outlook revised to stable	Moody's Investors Service
08 Nov 2021	Announcement of Periodic Review	Moody's announces completion of a periodic review of ratings of Teva Pharmaceutical Industries Ltd	Moody's Investors Service
15 Dec 2020	Announcement of Periodic Review	Moody's announces completion of a periodic review of ratings of Teva Pharmaceutical Industries Ltd	Moody's Investors Service
07 Apr 2020	Rating Action	Moody's affirms Teva's Ba2 CFR; upgrades liquidity rating to SGL-2	Moody's Investors Service
14 Jan 2020	Announcement of Periodic Review	Moody's announces completion of a periodic review of ratings of Teva Pharmaceutical Industries Ltd	Moody's Investors Service
14 Aug 2019	Rating Action	Moody's affirms Teva's Ba2 CFR; outlook revised to negative	Moody's Investors Service
15 Feb 2019	Announcement of Periodic Review	Moody's announces completion of a periodic review of ratings of Teva Pharmaceutical Industries Ltd	Moody's Investors Service
12 Jan 2018	Rating Action	Moody's downgrades Teva to Ba2; outlook stable	Moody's Investors Service
14 Dec 2017	Rating Action	Moody's places Teva's Baa3 ratings on review for downgrade	Moody's Investors Service
03 Aug 2017	Rating Action	Moody's downgrades Teva's ratings to Baa3 from Baa2; outlook negative	Moody's Investors Service
31 Jan 2017	Rating Action	Moody's Affirms Teva's Baa2 rating; outlook changed to negative	Moody's Investors Service
25 Aug 2016	Announcement	Moody's: Teva's Loss of Two Copaxone Patents is Credit Negative	Moody's Investors Service
02 Aug 2016	Rating Action	Moody's Downgrades Teva's ratings to Baa2; Outlook Stable	Moody's Investors Service
27 Jul 2015	Rating Action	Moody's Downgrades Teva's Rating to Baa1; Ratings on Review for Downgrade	Moody's Investors Service
21 Apr 2015	Rating Action	Moody's Affirms Teva's A3 Rating; changes outlook to negative	Moody's Investors Service
19 Feb 2015	Rating Action	Moody's Affirms Teva's A3 rating; outlook changed to stable	Moody's Investors Service
13 Jun 2013	Rating Action	Moody's Affirms Teva's A3 rating; outlook to negative	Moody's Investors Service
29 Mar 2012	Rating Action	Moody's rates Teva's new Euro notes A3; stable outlook	Moody's Investors Service
15 Jun 2010	Covenant Quality Assessment	Covenant Quality Pre-Sale Snapshot - Teva Pharmaceutical Finance III, LLC $_ Floating Rate Senior Notes due 2011 $_ _% Senior Notes due 2012 Teva Pharmaceutical Finance II, B.V. $_ _% Senior Notes due 2013	Moody's Investors Service
18 Mar 2010	Announcement	Moody's affirms Teva Pharmaceuticals at A3; stable outlook	Moody's Investors Service
13 Jan 2010	Rating Action	Moody's upgrades Teva Pharmaceuticals to A3 from Baa1	Moody's Investors Service
14 Oct 2009	Rating Action	Moody's upgrades Teva to Baa1 from Baa2; positive outlook	Moody's Investors Service
09 Jun 2009	Covenant Quality Assessment	Teva Pharmaceutical Finance Company, LLC - $500 million 5.550% Senior Notes due 2016; $1 billion 6.150% Senior Notes due 2036	Moody's Investors Service
18 May 2009	Rating Action	Moody's revises Teva's rating outlook to positive from stable	Moody's Investors Service
18 Jul 2008	Rating Action	Moody's affirms Teva Pharmaceuticals' Baa2 ratings	Moody's Investors Service
27 Jan 2006	Rating Action	MOODY'S ASSIGNS Baa2 RATINGS TO NEW SENIOR NOTES AND CONVERTIBLE DEBENTURES GUARANTEED BY TEVA PHARMACEUTICAL INDUSTRIES LIMITED ("TEVA"); STABLE RATING OUTLOOK	Moody's Investors Service

Resultados 1 - 29 de 29

Página 1 de 1 Next

Informes & Calificaciones

Productos & Soluciones

Noticias & Eventos

Usuarios Registrados

No se ha registrado?

Moody's Integrity Hotline

Via the Internet:

By telephone from the United States:

By telephone from outside the United States: